title: Heparin-induced modulation of insulin like-growth factor-I action on glucose level in control and fasted rats.
abstract: BACKGROUND
  Insulin like-growth factor-I (IGF-I) circulates in serum bound to IGF-binding proteins (IGFBPs), which are important regulators of IGF's biological activity. There are at least two classes of BPs: a high molecular weight complex (HMWBPs) and low molecular weight species (LMWBPs), with different affinity for IGF-I. Their specific role in regulation of IGF-I bioactivity is still controversial. Since: a) IGF-I plays an important role in glucose counter regulation; b) heparin was shown to alter IGF-I affinity to BPs; and c) fasting is known to change quantity and quality of serum BPs, we decided to measure the in vivo effect of heparin on blood IGF-I, BPs and glucose levels in control and fasted rats.
  
  
  METHODS
  Control and fasted rats were injected i.v. with heparin (500 UI/100 g body weight) every hour during 3 hours of the experiment. Blood samples were collected before and 15 or 30 minutes after heparin injection and used for determination of free and bound IGF-I (RIA), BPs (radiometric assay) and glucose level (glucose oxidase method).
  
  
  RESULTS
  Heparin treatment induced hypoglycaemia in fasted rats while it induced hyperglycemia in control one. The evidence was provided that heparin dissociates IGF-I from HMWBPs complex of control rat serum (predominant one in serum of these animals) and released IGF-I in turn is bound to LMWBPs--known as inhibitors of IGF-I dependent functions. In contrast, in fasted rat serum heparin dissociates IGF-I from LMWBPs (predominant complex in serum of these animals) making IGF-I free and available to stimulate IGF-I dependent functions. Therefore in control animals, which were administered heparin, blood glucose level was elevated and in fasted animals it was decreased.
  
  
  CONCLUSIONS
  The data presented raise the possibility that IGF-BPs may have an important role in IGF-dependent glucose counter regulation and that heparin or heparin-like molecules may affect the process. Medical significance of heparin-induced hyperglycaemia in control animals should be taken into consideration since heparin is commonly used in clinical practice.
authors.affiliation: Department of Biophysics, Medical Academy of Białystok, Białystok, Poland.
authors.forename: Z
authors.initials: Z
authors.lastname: Mnich
authors.forename: J
authors.initials: J
authors.lastname: Pałka
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002850:Chromatography, Gel; D005215:Fasting; D006493:Heparin / Q000097:blood / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood* / Q000302:isolation & purification; D007334:Insulin-Like Growth Factor I / Q000302:isolation & purification / Q000378:metabolism*; D008297:Male; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values
chemical_list: D001786:Blood Glucose; D006495:Heparin, Low-Molecular-Weight; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I; D006493:Heparin